| Year |
Citation |
Score |
| 2013 |
Sugita M, Kalota A, Gewirtz AM, Carroll M. Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression. Leukemia. 27: 1207-1210. PMID 23183425 DOI: 10.1038/Leu.2012.310 |
0.381 |
|
| 2012 |
Zhao H, Jin S, Gewirtz AM. The histone acetyltransferase TIP60 interacts with c-Myb and inactivates its transcriptional activity in human leukemia. The Journal of Biological Chemistry. 287: 925-34. PMID 22110127 DOI: 10.1074/Jbc.M111.279950 |
0.392 |
|
| 2011 |
Kozuka T, Sugita M, Shetzline S, Gewirtz AM, Nakata Y. c-Myb and GATA-3 cooperatively regulate IL-13 expression via conserved GATA-3 response element and recruit mixed lineage leukemia (MLL) for histone modification of the IL-13 locus. Journal of Immunology (Baltimore, Md. : 1950). 187: 5974-82. PMID 22039304 DOI: 10.4049/Jimmunol.1100550 |
0.374 |
|
| 2010 |
Nakata Y, Brignier AC, Jin S, Shen Y, Rudnick SI, Sugita M, Gewirtz AM. c-Myb, Menin, GATA-3, and MLL form a dynamic transcription complex that plays a pivotal role in human T helper type 2 cell development. Blood. 116: 1280-90. PMID 20484083 DOI: 10.1182/Blood-2009-05-223255 |
0.415 |
|
| 2010 |
Deleavey GF, Watts JK, Alain T, Robert F, Kalota A, Aishwarya V, Pelletier J, Gewirtz AM, Sonenberg N, Damha MJ. Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Research. 38: 4547-57. PMID 20413581 DOI: 10.1093/Nar/Gkq181 |
0.318 |
|
| 2010 |
Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz AM. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. The Journal of Clinical Investigation. 120: 593-606. PMID 20093773 DOI: 10.1172/Jci38030 |
0.404 |
|
| 2010 |
Brignier AC, Gewirtz AM. Embryonic and adult stem cell therapy. The Journal of Allergy and Clinical Immunology. 125: S336-44. PMID 20061008 DOI: 10.1016/J.Jaci.2009.09.032 |
0.343 |
|
| 2010 |
Kalota A, Gewirtz AM. A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. Blood. 115: 89-93. PMID 19880492 DOI: 10.1182/Blood-2009-06-227751 |
0.413 |
|
| 2009 |
Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, ... Gewirtz AM, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6732-9. PMID 19843663 DOI: 10.1158/1078-0432.Ccr-09-0842 |
0.307 |
|
| 2009 |
Zhao H, Kalota A, Jin S, Gewirtz AM. The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood. 113: 505-16. PMID 18818396 DOI: 10.1182/Blood-2008-01-136218 |
0.332 |
|
| 2009 |
Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz AM. C-Myb Associates with MLL1 through Menin, Augments MLL1's H3K4 Methylation Activity, and Regulates Hoxa9 and Meis1 Gene Expression in Primary Human Leukemia Cells. Blood. 114: 448-448. DOI: 10.1182/Blood.V114.22.448.448 |
0.44 |
|
| 2009 |
Zhao H, Jin S, Gewirtz AM. The Acetyl-Transferase Tip60 Interacts with c-Myb and Inactivates Its Transcriptional Activity in Human Leukemia. Blood. 114: 3981-3981. DOI: 10.1182/Blood.V114.22.3981.3981 |
0.391 |
|
| 2009 |
Kozuka T, Gewirtz AM, Nakata Y. C-Myb and GATA-3 Cooperatively Regulate Th2 Cytokine Gene Expression, with the Most Profound Effect On IL-13. Blood. 114: 3669-3669. DOI: 10.1182/Blood.V114.22.3669.3669 |
0.333 |
|
| 2008 |
Chou ST, Opalinska JB, Yao Y, Fernandes MA, Kalota A, Brooks JS, Choi JK, Gewirtz AM, Danet-Desnoyers GA, Nemiroff RL, Weiss MJ. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood. 112: 4503-6. PMID 18812473 DOI: 10.1182/Blood-2008-05-157859 |
0.372 |
|
| 2008 |
Rudnick SI, Swaminathan J, Sumaroka M, Liebhaber S, Gewirtz AM. Effects of local mRNA structure on posttranscriptional gene silencing. Proceedings of the National Academy of Sciences of the United States of America. 105: 13787-92. PMID 18784366 DOI: 10.1073/Pnas.0805781105 |
0.328 |
|
| 2008 |
Pattanayak V, Gifford LK, Lu P, Gewirtz AM. Observed versus predicted structure of fluorescent self-quenching reporter molecules (SQRM): caveats with respect to the use of "stem-loop" oligonucleotides as probes for mRNA folding. Rna (New York, N.Y.). 14: 657-65. PMID 18359781 DOI: 10.1261/Rna.890408 |
0.311 |
|
| 2008 |
Tang X, Swaminathan J, Gewirtz AM, Dmochowski IJ. Regulating gene expression in human leukemia cells using light-activated oligodeoxynucleotides. Nucleic Acids Research. 36: 559-69. PMID 18056083 DOI: 10.1093/Nar/Gkm1029 |
0.363 |
|
| 2008 |
Frey NV, Kalota A, Potuzak M, Shank D, Swider CR, Loren A, Stadtmauer E, Perl A, Cuker A, Konkle B, Sood S, Goldstein S, Kasner M, Porter DL, Luger SM, ... Gewirtz AM, et al. Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies Blood. 112: 4033-4033. DOI: 10.1182/Blood.V112.11.4033.4033 |
0.344 |
|
| 2008 |
Kalota A, Gewirtz AM. A Nonpeptidyl, Hydrazone Class, Thrombopoietin Receptor Agonist (TpoRA), SB559457, Selectively Kills Primary Human Myeloid Leukemia Cells Blood. 112: 2636-2636. DOI: 10.1182/Blood.V112.11.2636.2636 |
0.428 |
|
| 2008 |
Nakata Y, Jin S, Shen Y, Gewirtz AM. GATA-3 Requires C-Myb to Auto-Regulate Its Own Expression in Normal Human Peripheral Blood Lymphocytes Undergoing T Helper Type 2 (Th2) Cell Development Blood. 112: 2575-2575. DOI: 10.1182/Blood.V112.11.2575.2575 |
0.437 |
|
| 2007 |
Gewirtz AM. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. The Journal of Clinical Investigation. 117: 3612-4. PMID 18060018 DOI: 10.1172/Jci34274 |
0.312 |
|
| 2007 |
Drabsch Y, Hugo H, Zhang R, Dowhan DH, Miao YR, Gewirtz AM, Barry SC, Ramsay RG, Gonda TJ. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 104: 13762-7. PMID 17690249 DOI: 10.1073/Pnas.0700104104 |
0.316 |
|
| 2007 |
Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA, Langerak AW, Montpellier B, Nadel B, Walrafen P, Delattre O, Aurias A, Leblanc T, Dombret H, Gewirtz AM, et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood. 110: 1251-61. PMID 17452517 DOI: 10.1182/Blood-2006-12-064683 |
0.331 |
|
| 2007 |
Nakata Y, Shetzline S, Sakashita C, Kalota A, Rallapalli R, Rudnick SI, Zhang Y, Emerson SG, Gewirtz AM. c-Myb contributes to G2/M cell cycle transition in human hematopoietic cells by direct regulation of cyclin B1 expression. Molecular and Cellular Biology. 27: 2048-58. PMID 17242210 DOI: 10.1128/Mcb.01100-06 |
0.432 |
|
| 2007 |
Gewirtz AM. RNA targeted therapeutics for hematologic malignancies. Blood Cells, Molecules & Diseases. 38: 117-9. PMID 17215146 DOI: 10.1016/J.Bcmd.2006.10.162 |
0.345 |
|
| 2007 |
Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela J, Dik WA, Langerak AW, Montpellier B, Nadel B, Walrafen P, Aurias A, Leblanc T, Dombret H, Gewirtz AM, Baruchel A, et al. A New Subtype of T-Cell Acute Leukemia in Very Young Children Is Defined by a Translocation Targeting the C-MYB Oncogene, and a Specific Gene Expression Signature. Blood. 110: 982-982. DOI: 10.1182/Blood.V110.11.982.982 |
0.353 |
|
| 2007 |
Jin S, Zhao H, Gewirtz AM. c-Myb Functions as a Co-Activator of MLL1 through Menin, and More Globally Affects Histone Methylation. Blood. 110: 827-827. DOI: 10.1182/Blood.V110.11.827.827 |
0.407 |
|
| 2007 |
Nakata Y, Gewirtz AM. c-Myb Contributes to Normal Human Peripheral Blood T Helper 2 Cell Development through Regulation of GATA-3 Expression. Blood. 110: 793-793. DOI: 10.1182/Blood.V110.11.793.793 |
0.449 |
|
| 2006 |
Opalinska JB, Kalota A, Chattopadhyaya J, Damha M, Gewirtz AM. Nucleic acid therapeutics for hematologic malignancies--theoretical considerations. Annals of the New York Academy of Sciences. 1082: 124-36. PMID 17145934 DOI: 10.1196/Annals.1348.002 |
0.321 |
|
| 2006 |
Nakata Y, Tomkowicz B, Gewirtz AM, Ptasznik A. Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine receptors in normal human CD34+ marrow cells. Blood. 107: 4234-9. PMID 16467205 DOI: 10.1182/Blood-2005-08-3343 |
0.4 |
|
| 2006 |
Kalota A, Karabon L, Swider CR, Viazovkina E, Elzagheid M, Damha MJ, Gewirtz AM. 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing. Nucleic Acids Research. 34: 451-61. PMID 16421272 DOI: 10.1093/Nar/Gkj455 |
0.337 |
|
| 2006 |
Shetzline SE, Conlon J, Swider C, Thalheim L, Gewirtz AM. The Proto-Oncogene Myb Augments Transcription of the Neuropeptide Neuromedin U in Human Myeloid Leukemias. Blood. 108: 2254-2254. DOI: 10.1182/Blood.V108.11.2254.2254 |
0.459 |
|
| 2006 |
Kalota A, Gewirtz AM. Computationally Designed, Small Molecule Inhibitors of Tubulin Inhibit the Growth of Gleevec Resistant Chronic Myelogenous Leukemia Cells. Blood. 108: 2173-2173. DOI: 10.1182/Blood.V108.11.2173.2173 |
0.381 |
|
| 2006 |
Jin S, Zhao H, Gewirtz AM. c-Myb-Interacting Proteins and Their Functions. Blood. 108: 1423-1423. DOI: 10.1182/Blood.V108.11.1423.1423 |
0.433 |
|
| 2006 |
Zhao H, Jin S, Gewirtz AM. MDM2 Promotes Ubiquitin-Independent Degradation of HoxA9: Implications for MLL-Fusion Protein Mediated Transformation. Blood. 108: 1418-1418. DOI: 10.1182/Blood.V108.11.1418.1418 |
0.387 |
|
| 2006 |
Nakata Y, Shetzline S, Sakashita C, Kalota A, Rudnick SI, Gewirtz AM. Myb Family Transcription Factors Contribute to G2/M Cell Cycle Transition in Normal and Malignant Hematopoietic Cells by Direct Regulation of Cyclin B1 Expression. Blood. 108: 1115-1115. DOI: 10.1182/Blood.V108.11.1115.1115 |
0.415 |
|
| 2006 |
Rudnick SI, Gewirtz AM. 716. Differential Effects of Secondary Structure on Antisense Oligonucleotide (AON) and Short Interfering RNA (siRNA) Mediated mRNA Cleavage Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.795 |
0.332 |
|
| 2005 |
Opalinska JB, Gewirtz AM. Rationally targeted, conformationally constrained, oxetane-modified oligonucleotides demonstrate efficient gene-silencing activity in a cellular system. Annals of the New York Academy of Sciences. 1058: 39-51. PMID 16394124 DOI: 10.1196/Annals.1359.007 |
0.325 |
|
| 2005 |
Hexner EO, Gewirtz AM. RNA interference for treating haematological malignancies. Expert Opinion On Biological Therapy. 5: 1585-92. PMID 16318422 DOI: 10.1517/14712598.5.12.1585 |
0.332 |
|
| 2005 |
Gifford LK, Jordan D, Pattanayak V, Vernovsky K, Do BT, Gewirtz AM, Lu P. Stemless self-quenching reporter molecules identify target sequences in mRNA. Analytical Biochemistry. 347: 77-88. PMID 16246289 DOI: 10.1016/J.Ab.2005.08.030 |
0.331 |
|
| 2005 |
Nakata Y, Kim TK, Shetzline S, Gewirtz AM. Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer. Critical Reviews in Eukaryotic Gene Expression. 15: 163-82. PMID 16022634 DOI: 10.1615/Critreveukaryotgeneexpr.V15.I2.50 |
0.343 |
|
| 2005 |
Opalinska JB, Machalinski B, Ratajczak J, Ratajczak MZ, Gewirtz AM. Multigene targeting with antisense oligodeoxynucleotides: an exploratory study using primary human leukemia cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4948-54. PMID 16000594 DOI: 10.1158/1078-0432.Ccr-05-0106 |
0.448 |
|
| 2005 |
Gifford LK, Opalinska JB, Jordan D, Pattanayak V, Greenham P, Kalota A, Robbins M, Vernovsky K, Rodriguez LC, Do BT, Lu P, Gewirtz AM. Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching fluorescent reporter molecules. Nucleic Acids Research. 33: e28. PMID 15718294 DOI: 10.1093/Nar/Gni024 |
0.327 |
|
| 2005 |
Civin CI, Gewirtz AM, Hawley RG, Goodell MA. Advancing the fast-paced field of stem cell research: stem cells increases from 6 to 10 issues in its 23rd year of publication. Stem Cells (Dayton, Ohio). 23: 1-2. PMID 15625117 DOI: 10.1634/Stemcells.2005-Ed.1 |
0.314 |
|
| 2005 |
Carroll M, Kim TK, Higashino K, Gewirtz AM. Acute Myeloid Leukemia Cells Require STAT5 for Survival. Blood. 106: 1616-1616. DOI: 10.1182/Blood.V106.11.1616.1616 |
0.406 |
|
| 2005 |
Nakata Y, Shetzline S, Sakashita C, Kalota A, Ptasznik A, Zhang Y, Emerson SG, Gewirtz AM. c-Myb Plays a Role InG2/M Cell Cycle Transition by Direct Regulation of Cyclin B1 Expression in Hematopoietic Cells. Blood. 106: 1355-1355. DOI: 10.1182/Blood.V106.11.1355.1355 |
0.421 |
|
| 2005 |
Thalheim LB, Shetzline SE, Swider CR, Gewirtz AM. Transcriptional Regulation of the Intra-S-Phase Regulator CDC7 in Human Myeloid Leukemic Cells: A New Downstream Target of the C-Myb Protooncogene. Blood. 106: 1354-1354. DOI: 10.1182/Blood.V106.11.1354.1354 |
0.461 |
|
| 2004 |
Opalinska JB, Kalota A, Gifford LK, Lu P, Jen KY, Pradeepkumar PI, Barman J, Kim TK, Swider CR, Chattopadhyaya J, Gewirtz AM. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules. Nucleic Acids Research. 32: 5791-9. PMID 15514112 DOI: 10.1093/Nar/Gkh893 |
0.38 |
|
| 2004 |
Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nature Medicine. 10: 1187-9. PMID 15502840 DOI: 10.1038/Nm1127 |
0.36 |
|
| 2004 |
Shetzline SE, Rallapalli R, Dowd KJ, Zou S, Nakata Y, Swider CR, Kalota A, Choi JK, Gewirtz AM. Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood. 104: 1833-40. PMID 15187020 DOI: 10.1182/Blood-2003-10-3577 |
0.458 |
|
| 2004 |
Kalota A, Shetzline SE, Gewirtz AM. Progress in the development of nucleic acid therapeutics for cancer. Cancer Biology & Therapy. 3: 4-12. PMID 14726654 DOI: 10.4161/Cbt.3.1.517 |
0.306 |
|
| 2004 |
Gewirtz AM. Dr. Marshall A. Lichtman: The Wit and Wisdom of One of Stem Cells' Founding Fathers Stem Cells. 22: 876-876. DOI: 10.1634/Stemcells.22-6-876 |
0.329 |
|
| 2004 |
Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Targeting Lyn Kinase with Short Interfering RNA (siRNA)-A Novel Therapeutic Strategy for Drug Resistant Chronic Myelogenous Leukemia (CML). Blood. 104: 554-554. DOI: 10.1182/Blood.V104.11.554.554 |
0.43 |
|
| 2004 |
Gangenahalli GU, Millholland JM, Kalota A, Bennett P, Sutherland BM, Gewirtz AM. Countering Low-Linear Energy Transfer (LET) and High-LET Radiation Exposure with Pro-Methyl Hoechst (PMH) and EUK-134 (Mg-Salen Complex): Radioprotection of Normal Human CD34 + Cells in a Simulated Deep Space Environment. Blood. 104: 4158-4158. DOI: 10.1182/Blood.V104.11.4158.4158 |
0.34 |
|
| 2004 |
Kim TK, Carroll M, Gewirtz AM. Acute Myeloid Leukemia Cells Contain Constitutively Activated STAT3 and Require STAT3 for Survival. Blood. 104: 3368-3368. DOI: 10.1182/Blood.V104.11.3368.3368 |
0.43 |
|
| 2004 |
Kalota A, Brennan K, Erickson-Miller CL, Danet G, Carroll M, Gewirtz AM. Effects of SB559457, a Novel Small Molecule Thrombopoietin Receptor (TpoR) Agonist, on Human Hematopoietic Cell Growth and Differentiation. Blood. 104: 2913-2913. DOI: 10.1182/Blood.V104.11.2913.2913 |
0.41 |
|
| 2004 |
Shetzline SE, Hsu J, Thalheim L, Choi JK, Gewirtz AM. Intra-S-Phase Regulator cdc7 Is a Gene Target of the c-Myb Proto-Oncogene in Human Leukemias. Blood. 104: 2039-2039. DOI: 10.1182/Blood.V104.11.2039.2039 |
0.447 |
|
| 2003 |
Opalinska JB, Gewirtz AM. Therapeutic potential of antisense nucleic acid molecules. Science's Stke : Signal Transduction Knowledge Environment. 2003: pe47. PMID 14583589 DOI: 10.1126/Stke.2003.206.Pe47 |
0.366 |
|
| 2003 |
Civin CI, Gewirtz AM, Hawley RG. Stem Cells: 21 Years Old, With the Best Yet to Come Stem Cells. 21: 513-513. DOI: 10.1634/Stemcells.21-5-513 |
0.306 |
|
| 2002 |
Ptasznik A, Urbanowska E, Chinta S, Costa MA, Katz BA, Stanislaus MA, Demir G, Linnekin D, Pan ZK, Gewirtz AM. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. The Journal of Experimental Medicine. 196: 667-78. PMID 12208881 DOI: 10.1084/Jem.20020519 |
0.31 |
|
| 2002 |
Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: basic principles and recent applications. Nature Reviews. Drug Discovery. 1: 503-14. PMID 12120257 DOI: 10.1038/Nrd837 |
0.319 |
|
| 2002 |
Luger SM, O'Brien SG, Ratajczak J, Ratajczak MZ, Mick R, Stadtmauer EA, Nowell PC, Goldman JM, Gewirtz AM. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood. 99: 1150-8. PMID 11830460 DOI: 10.1182/Blood.V99.4.1150 |
0.384 |
|
| 2002 |
Civin CI, Gewirtz AM. Stem Cells 20th Anniversary Stem Cells. 20: 1-2. DOI: 10.1634/Stemcells.20-1-1 |
0.315 |
|
| 2001 |
Majka M, Janowska-Wieczorek A, Ratajczak J, Ehrenman K, Pietrzkowski Z, Kowalska MA, Gewirtz AM, Emerson SG, Ratajczak MZ. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 97: 3075-3085. PMID 11342433 DOI: 10.1182/Blood.V97.10.3075 |
0.386 |
|
| 2001 |
Pertusini E, Ratajczak J, Majka M, Vaughn D, Ratajczak MZ, Gewirtz AM. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood. 97: 638-644. PMID 11157479 DOI: 10.1182/Blood.V97.3.638 |
0.344 |
|
| 2000 |
Majka M, Ratajczak J, Lee B, Honczarenko M, Douglas R, Kowalska MA, Silberstein L, Gewirtz AM, Ratajczak MZ. The Role of HIV‐Related Chemokine Receptors and Chemokines in Human Erythropoiesis in Vitro Stem Cells. 18: 128-138. PMID 10742385 DOI: 10.1634/Stemcells.18-2-128 |
0.37 |
|
| 2000 |
Ratajczak J, Pertussini E, Majka M, Vaughn D, Ratajczak M, Gewirtz A. Investigation of the platelet sparing mechanism of paclitaxel and carboplatin chemotherapy Experimental Hematology. 28: 1492. DOI: 10.1016/S0301-472X(00)00657-3 |
0.334 |
|
| 2000 |
Majka M, Ratajczak J, Gewirtz AM, Ratajczak MZ. PI-3k-Akt axis inhibits apoptosis in normal human megakaryoblasts and is efficiently activated by thrombopoietin Experimental Hematology. 28: 1492. DOI: 10.1016/S0301-472X(00)00564-6 |
0.344 |
|
| 1999 |
Agarwal N, Gewirtz AM. Oligonucleotide therapeutics for hematologic disorders Biochimica Et Biophysica Acta - Gene Structure and Expression. 1489: 85-96. PMID 10806999 DOI: 10.1016/S0167-4781(99)00142-6 |
0.362 |
|
| 1999 |
Gewirtz AM. Myb targeted therapeutics for the treatment of human malignancies. Oncogene. 18: 3056-3062. PMID 10378701 DOI: 10.1038/Sj.Onc.1202785 |
0.317 |
|
| 1999 |
Sokol DL, Gewirtz AM. Monitoring Antisense Oligodeoxynucleotide Activity in Hematopoietic Cells Methods. 17: 219-230. PMID 10080907 DOI: 10.1006/Meth.1998.0732 |
0.355 |
|
| 1999 |
Kowalska MA, Ratajczak J, Hoxie J, Brass LF, Gewirtz A, Poncz M, Ratajczak MZ. Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: Determination of response to stromal- derived factor-1 by megakaryocytes and platelets British Journal of Haematology. 104: 220-229. PMID 10050701 DOI: 10.1046/J.1365-2141.1999.01169.X |
0.311 |
|
| 1998 |
Sokol DL, Zhang X, Lu P, Gewirtz AM. Real time detection of DNA·RNA hybridization in living cells Proceedings of the National Academy of Sciences of the United States of America. 95: 11538-11543. PMID 9751701 DOI: 10.1073/Pnas.95.20.11538 |
0.349 |
|
| 1998 |
Ratajczak M, Pletcher C, Marlicz W, Machalinski B, Moore J, Wasik M, Ratajczak J, Gewirtz A. CD34 + , kit + , rhodamine123 low phenotype identifies a marrow cell population highly enriched for human hematopoietic stem cells Leukemia. 12: 942-950. PMID 9639424 DOI: 10.1038/Sj.Leu.2401027 |
0.417 |
|
| 1998 |
Gewirtz AM. Antisense oligonucleotide therapeutics for human leukemia. Current Opinion in Hematology. 5: 59-71. PMID 9515205 DOI: 10.1097/00062752-199801000-00011 |
0.374 |
|
| 1998 |
Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic Acid Therapeutics: State of the Art and Future Prospects Blood. 92: 712-736. DOI: 10.1182/Blood.V92.3.712.415A32_712_736 |
0.315 |
|
| 1998 |
Wlodarski P, Wasik M, Ratajczak MZ, Sevignani C, Hoser G, Kawiak J, Gewirtz AM, Calabretta B, Skorski T. Role of p53 in Hematopoietic Recovery After Cytotoxic Treatment Blood. 91: 2998-3006. DOI: 10.1182/Blood.V91.8.2998.2998_2998_3006 |
0.354 |
|
| 1998 |
Ratajczak MZ, Perrotti D, Melotti P, Powzaniuk M, Calabretta B, Onodera K, Kregenow DA, Machalinski B, Gewirtz AM. Myb and Ets Proteins Are Candidate Regulators of c-kit Expression in Human Hematopoietic Cells Blood. 91: 1934-1946. DOI: 10.1182/Blood.V91.6.1934.1934_1934_1946 |
0.406 |
|
| 1998 |
Ratajczak MZ, Ratajczak J, Machalinski B, Mick R, Gewirtz AM. In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopenia. Blood. 91: 353-359. DOI: 10.1182/Blood.V91.1.353 |
0.37 |
|
| 1997 |
Ratajczak J, Marlicz W, Keidel A, Machalinski B, Ratajczak MZ, Gewirtz AM. Effect of Interleukin-1 α and Interleukin-1 β on Erythroid Progenitor Cell Growth in Serum Free Cultures: An In Vitro Study Relevant to the Pathogenesis of the Anemia of Chronic Disease. Hematology. 2: 21-28. PMID 27406723 DOI: 10.1080/10245332.1997.11746316 |
0.328 |
|
| 1997 |
Gewirtz AM. Antisense oligonucleotide therapeutics for human leukemia. Critical Reviews in Oncogenesis. 8: 93-109. PMID 9516088 DOI: 10.1615/Critrevoncog.V8.I1.50 |
0.372 |
|
| 1997 |
Ratajczak MZ, Marlicz W, Ratajczak J, Wasik M, Machalinski B, Carter A, Gewirtz AM. Effect of hepatocyte growth factor on early human haemopoietic cell development. British Journal of Haematology. 99: 228-236. PMID 9359529 DOI: 10.1046/J.1365-2141.1997.3563170.X |
0.402 |
|
| 1997 |
Ratajczak MZ, Ratajczak J, Marlicz W, Pletcher CH, Machalinski B, Moore J, Hung H, Gewirtz AM. Recombinant human thrombopoietin (TPO) stimulates erythropoiesis by inhibiting erythroid progenitor cell apoptosis. British Journal of Haematology. 98: 8-17. PMID 9233556 DOI: 10.1046/J.1365-2141.1997.1802997.X |
0.359 |
|
| 1996 |
Gewirtz AM. Methodologic approaches for investigating human megakaryocyte development at a molecular level. Stem Cells. 14: 206-211. PMID 11012223 DOI: 10.1002/Stem.5530140727 |
0.387 |
|
| 1996 |
Sokol DL, Gewirtz AM. Gene Therapy: Basic Concepts and Recent Advances Critical Reviews in Eukaryotic Gene Expression. 6: 29-57. PMID 8882306 DOI: 10.1615/Critreveukargeneexpr.V6.I1.30 |
0.386 |
|
| 1996 |
Ratajczak MZ, Ratajczak J, Ford J, Kregenow R, Marlicz W, Gewirtz AM. FLT3/FLK-2 (STK-1) Ligand Does Not Stimulate Human Megakaryopoiesis In Vitro Stem Cells. 14: 146-150. PMID 8820960 DOI: 10.1002/Stem.140146 |
0.324 |
|
| 1996 |
Gewirtz AM. The c-myb proto-oncogene: a novel target for human gene therapy. Cancer Treatment and Research. 84: 93-112. PMID 8724627 DOI: 10.1007/978-1-4613-1261-1_5 |
0.403 |
|
| 1996 |
Ratajczak MZ, Ratajczak J, Skorska M, Marlicz W, Calabretta B, Pletcher CH, Moore J, Gewirtz AM. Effect of basic (FGF-2) and acidic (FGF-1) fibroblast growth factors on early haemopoietic cell development British Journal of Haematology. 93: 772-782. PMID 8703802 DOI: 10.1046/J.1365-2141.1996.D01-1736.X |
0.394 |
|
| 1996 |
Luger S, Ratajczak J, Ratajczak M, Kuczynski W, DiPaola R, Ngo W, Clevenger C, Gewirtz A. A functional analysis of protooncogene Vav's role in adult human hematopoiesis Blood. 87: 1326-1334. DOI: 10.1182/Blood.V87.4.1326.Bloodjournal8741326 |
0.453 |
|
| 1995 |
Clevenger CV, Ngo W, Sokol DL, Luger SM, Gewirtz AM. Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line. The Journal of Biological Chemistry. 270: 13246-53. PMID 7768923 DOI: 10.1074/Jbc.270.22.13246 |
0.34 |
|
| 1995 |
Hijiya N, Gewirtz AM. Oncogenes, protooncogenes, and tumor suppressor genes in acute myelogenous leukemia Journal of Pediatric Hematology Oncology. 17: 101-112. PMID 7749759 DOI: 10.1097/00043426-199505000-00003 |
0.386 |
|
| 1995 |
Gewirtz A, Zhang J, Ratajczak J, Ratajczak M, Park K, Li C, Yan Z, Poncz M. Chemokine regulation of human megakaryocytopoiesis Blood. 86: 2559-2567. DOI: 10.1182/Blood.V86.7.2559.Bloodjournal8672559 |
0.343 |
|
| 1995 |
Gewirtz AM. Megakaryocytopoiesis: the state of the art. Thrombosis and Haemostasis. 74: 204-209. DOI: 10.1055/S-0038-1642677 |
0.364 |
|
| 1994 |
Hijiya N, Zhang J, Ratajczak MZ, Kant JA, Deriel K, Herlyn M, Zon G, Gewirtz AM. Biologic and therapeutic significance of MYB expression in human melanoma Proceedings of the National Academy of Sciences of the United States of America. 91: 4499-4503. PMID 8183937 DOI: 10.1073/Pnas.91.10.4499 |
0.41 |
|
| 1994 |
Ratajczak MZ, Kuczynski WI, Onodera K, Moore J, Ratajczak J, Kregenow DA, DeRiel K, Gewirtz AM. A Reappraisal Of The Role Of Insulin-Like Growth Factor I In The Regulation Of Human Hematopoiesis Journal of Clinical Investigation. 94: 320-327. PMID 8040273 DOI: 10.1172/Jci117324 |
0.366 |
|
| 1994 |
Ratajczak MZ, Ratajczak J, Kregenow DA, Gewirtz AM. Growth factor stimulation of cryopreserved CD34+ bone marrow cells intended for transplant: An in vitro study to determine optimal timing of exposure to early acting cytokines Stem Cells. 12: 599-603. PMID 7533578 DOI: 10.1002/Stem.5530120607 |
0.36 |
|
| 1993 |
Calabretta B, Venturelli D, Gewirtz AM. Functional Significance of c-myb Expression in Normal and Leukemic Hematopoiesis Cancer Investigation. 11: 191-197. PMID 8462020 DOI: 10.3109/07357909309024839 |
0.327 |
|
| 1993 |
Migliaccio AR, Migliaccio G, Mancini G, Ratajczak M, Gewirtz AM, Adamson JW. Induction of the murine "W phenotype" in long-term cultures of human cord blood cells by c-kit antisense oligomers. Journal of Cellular Physiology. 157: 158-63. PMID 7691834 DOI: 10.1002/Jcp.1041570120 |
0.412 |
|
| 1993 |
Gewirtz AM. Oligodeoxynucleotide-based therapeutics for human leukemias. Stem Cells. 11: 96-103. PMID 7507759 DOI: 10.1002/Stem.5530110922 |
0.444 |
|
| 1993 |
Gewirtz AM. Potential Therapeutic Applications of Antisense Oligodeoxynucleotides in the Treatment of Chronic Myelogenous Leukemia Leukemia & Lymphoma. 11: 131-137. PMID 7504543 DOI: 10.3109/10428199309047876 |
0.446 |
|
| 1992 |
Gewirtz AM, Shapiro C, Shen YM, Boyd R, Colman RW. Cellular and molecular regulation of factor V expression in human megakaryocytes. Journal of Cellular Physiology. 153: 277-287. PMID 1429848 DOI: 10.1002/Jcp.1041530207 |
0.353 |
|
| 1992 |
Ratajczak WZ, Luger SM, Gewirtz AM. The c-kit proto-oncogene in normal and malignant human hematopoiesis. Stem Cells. 10: 205-214. PMID 1379619 DOI: 10.1002/Stem.5530100403 |
0.444 |
|
| 1992 |
Ratajczak M, Luger S, DeRiel K, Abrahm J, Calabretta B, Gewirtz AM. Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proceedings of the National Academy of Sciences of the United States of America. 89: 1710-1714. PMID 1371882 DOI: 10.1073/Pnas.89.5.1710 |
0.454 |
|
| 1992 |
Hijiya N, Gewirtz AM. Oncogenes, molecular medicine, and bone marrow transplantation. Journal of Hematotherapy. 1: 369-378. PMID 1345679 DOI: 10.1089/Scd.1.1992.1.369 |
0.321 |
|
| 1992 |
Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, Gewirtz AM. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides Proceedings of the National Academy of Sciences of the United States of America. 89: 11823-11827. PMID 1281545 DOI: 10.1073/Pnas.89.24.11823 |
0.428 |
|
| 1992 |
Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P, Gewirtz AM. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides Blood. 79: 1956-1961. DOI: 10.1182/Blood.V79.8.1956.Bloodjournal7981956 |
0.408 |
|
| 1991 |
Gewirtz AM, Calabretta B. Role of the c-myb and c-abl protooncogenes in human hematopoiesis. Annals of the New York Academy of Sciences. 628: 63-73. PMID 2069323 DOI: 10.1111/J.1749-6632.1991.Tb17224.X |
0.312 |
|
| 1991 |
Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science (New York, N.Y.). 253: 562-5. PMID 1857987 DOI: 10.1126/Science.1857987 |
0.442 |
|
| 1990 |
Gewirtz AM, Calabretta B. Molecular regulation of human megakaryocyte development. Stem Cells. 8: 267-276. PMID 2205664 DOI: 10.1002/Stem.5530080411 |
0.406 |
|
| 1989 |
Anfossi G, Gewirtz AM, Calabretta B. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proceedings of the National Academy of Sciences of the United States of America. 86: 3379-3383. PMID 2541445 DOI: 10.1073/Pnas.86.9.3379 |
0.436 |
|
| 1988 |
Venturelli D, Lange B, Narni F, Selleri L, Mariano MT, Torelli U, Gewirtz AM, Calabretta B. Prognostic significance of "short-term" effects of chemotherapy on MYC and histone H3 mRNA levels in acute leukemia patients Proceedings of the National Academy of Sciences of the United States of America. 85: 3590-3594. PMID 3285345 DOI: 10.1073/Pnas.85.10.3590 |
0.313 |
|
| Show low-probability matches. |